Adverse Event reporting information can be found in footer
Request a Meeting
Support your patients prescribed CORTIMENT® to treat their UC by simply emailing a link to this leaflet which contains FAQs such as:
Support your patients prescribed CORTIMENT® to treat their MC by simply emailing a link to this leaflet which contains FAQs such as:
The CORTIMENT Product Monograph contains a comprehensive overview of CORTIMENT’s use within its licensed therapeutic areas. You will find information on Ulcerative and Microscopic Colitis, the rationale for CORTIMENT’s development, its mechanism of action, and clinical data from randomised controlled trials and real world evidence.
The CORE Practice is a Real World Evidence study published by Danese S, et al. J Crohns Colitis. 2019;13(supplement 1):296-297
This looks at results from a prospective, multi-centre, observational cohort study assessing the effectiveness of CORTIMENT® for mild to moderate active UC.
iSTART (iSupport Therapy-Access to Rapid Treatment) is a Ferring Pharmaceuticals initiative consisting of a global expert panel to improve patient-centred management for mild to moderate UC.
This leaflet provides useful information including:
This leaflet provides a summary of key Real World Evidence studies using CORTIMENT®for the treatment of flaring Ulcerative Colitis:
This leaflet provides an overview of Microscopic Colitis and how CORTIMENT® can be used to treat patients with Active Microscopic Colitis
Job Code: UK-COR-2200064 - Date of preparation: November 2022